In response to the alarming rise in global cancer cases, Fortis Healthcare has announced substantial investments to bolster its oncology facilities. Ashutosh Raghuvanshi, the CEO of Fortis Healthcare, emphasized the company’s strategic focus on core specialties, with oncology playing a pivotal role.
Oncology currently accounts for a significant 13% of Fortis Healthcare’s revenue, a number expected to increase as the company ramps up its efforts in this sector. ‘While cardiac sciences remain a significant revenue driver at 23%, the growing contribution of oncology underscores the urgent need for enhanced cancer care facilities,’ stated Raghuvanshi.
To meet this demand, Fortis Healthcare is directing investments into cutting-edge technologies such as MR LINAC and Gamma Knife. The MR LINAC technology combines magnetic resonance imaging (MRI) with radiation therapy, offering precise targeting and treatment for various cancers. The addition of Gamma Knife technology will substantially enhance Fortis Healthcare’s oncology capabilities, particularly in North India.
Furthermore, Fortis Healthcare is actively expanding its bed capacity across hospitals and planning significant additions in various locations. This strategic move aligns with a larger trend seen among major hospitals like Max Healthcare and Narayana Health, where investments in oncology facilities are increasing.
Raghuvanshi explained that lifestyle changes and environmental factors are contributing to the surge in cancer cases globally. Both public and private sectors are now focusing on early diagnosis and affordable treatment options to meet the escalating demand for cancer care.
